VCVicente Cambra-Cortés

Vicente Cambra-Cortés

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Vicente Cambra-Cortés has a total of 9 co-authors. Here are the top co-authors by number of shared publications:

  • Andrea Jiménez-Franco

    Unitat de Recerca Biomédica, Hospital Universitari de Sant Joan, Institut d’Investigació Sanitària Pere Virgili, Universitat Rovira i Virgili, Av. Dr. Josep Laporte 2, 43204 Reus, Spain

    2 shared publications
  • Isabel Fort-Gallifa

    Facultat de Medicina i Ciències de la Salut, University Rovira i Virgili, 43003 Tarragona, Spain

    2 shared publications
  • Jordi Camps

    Unitat de Recerca Biomédica, Hospital Universitari de Sant Joan, Institut d’Investigació Sanitària Pere Virgili, Universitat Rovira i Virgili, Av. Dr. Josep Laporte 2, 43204 Reus, Spain

    2 shared publications
  • Jorge Joven

    Unitat de Recerca Biomédica, Hospital Universitari de Sant Joan, Institut d’Investigació Sanitària Pere Virgili, Universitat Rovira i Virgili, Av. Dr. Josep Laporte 2, 43204 Reus, Spain

    2 shared publications
  • Marta Canela-Capdevila

    Unitat de Recerca Biomédica, Hospital Universitari de Sant Joan, Institut d’Investigació Sanitària Pere Virgili, Universitat Rovira i Virgili, Av. Dr. Josep Laporte 2, 43204 Reus, Spain

    2 shared publications
  • Meritxell Arenas

    Unitat de Recerca Biomédica, Hospital Universitari de Sant Joan, Institut d’Investigació Sanitària Pere Virgili, Universitat Rovira i Virgili, Av. Dr. Josep Laporte 2, 43204 Reus, Spain

    2 shared publications

Latest Publications

  • Open Access

    Post-Radiotherapy Changes in Circulating Dodecanoic Acid Identify Metabolic Phenotypes Associated with Recurrence in Breast Cancer

    by Andrea Jiménez-Franco, Vicente Cambra-Cortés, Raquel García-Pablo, Marta Canela-Capdevila, Rocío Benavides-Villarreal, Xavier Gabaldó-Barrios, Isabel Fort-Gallifa, Jordi Camps, Jorge Joven, Meritxell Arenas

    Research on biomarkers reflecting tumor biology and systemic metabolism is crucial for improving the accuracy and personalization of breast cancer (BC) prognosis. We investigated circulating dodecanoic acid in 229 patients undergoing radiotherapy (RT) and assessed its association with progression-free survival and overall survival over six years. Patients were classified into two phenotypes based on post-RT changes in dodecanoic acid: The Increase Phenotype (IP) had lower baseline concentrations and showed a post-RT rise, whereas the Decrease Phenotype (DP) had higher pre-RT levels and declined after treatment. Dodecanoic acid levels were lower in tumors than in peritumoral samples, and their association with phenotypes varied by sampling region, suggesting that systemic changes reflect broader metabolic adaptations rather than local tissue concentrations. Post-RT increases in dodecanoic acid were associated with higher paraoxonase-1 activity, suggesting a link with antioxidant status. Patients in the IP group had a significantly lower risk of progression than those in the DP group, whereas no significant differences in overall survival were observed. These findings highlight the potential utility of dodecanoic acid measurement as a prognostic biomarker and suggest that modulating fatty acid metabolism could be explored as a therapeutic strategy.


  • Open Access

    Post-Radiotherapy Changes of Circulating Dodecanoic Acid Identify Metabolic Phenotypes Associated with Recurrence in Breast Cancer

    by Andrea Jiménez-Franco, Vicente Cambra-Cortés, Raquel García-Pablo, Marta Canela-Capdevila, Rocío Benavides-Villarreal, Xavier Gabaldó-Barrios, Isabel Fort-Gallifa, Jordi Camps, Jorge Joven, Meritxell Arenas

    Research on biomarkers reflecting tumor biology and systemic metabolism is crucial for improving the accuracy and personalization of breast cancer (BC) prognosis. We investigated circulating dodecanoic acid in 229 patients undergoing radiotherapy (RT) and assessed its association with progression-free survival and overall survival over six years. Patients were classified into two phenotypes based on post-RT changes in dodecanoic acid: The Increase Phenotype (IP) had lower baseline concentrations and showed a post-RT rise, whereas the Decrease Phenotype (DP) had higher pre-RT levels and declined after treatment. Dodecanoic acid levels were lower in tumors than in peritumoral samples, and their association with phenotypes varied by sampling region, suggesting that systemic changes reflect broader metabolic adaptations rather than local tissue concentrations. Post-RT increases in dodecanoic acid were associated with higher paraoxonase-1 activity, suggesting a link with antioxidant status. Patients in the IP group had a significantly lower risk of progression than those in the DP group, whereas no significant differences in overall survival were observed. These findings highlight the potential utility of dodecanoic acid measurement as a prognostic biomarker and suggest that modulating fatty acid metabolism could be explored as a therapeutic strategy.